Stock Info (+) Info bourse (+)

TSX: SVA  |  OTC: SEOVF

The Path to a Regenerative Cure Le chemin vers un traitement régénérateur

The Path to a Regenerative Cure Le chemin vers un traitement régénérateur

Sernova is a regenerative medicine therapeutics company Sernova est une société de traitement en médecine régénérative

Developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is the development of technologies for the treatment of patients with insulin-dependent (T1) diabetes, hemophilia A and thyroid disease. Développer des technologies de plate-forme thérapeutique pour traiter les maladies chroniques grâce à une approche de médecine régénérative. L’objectif principal de Sernova est la mise au point de technologies de traitement du diabète insulino-dépendant (T1), de l’hémophilie A et de la thyroïde.

About Sernova, Corp. À propos de Sernova, Corp.

Sernova is committed to the development and clinical advancement of its products for metabolic, hematological and other chronic diseases using therapeutic cells transplanted into a patented implanted medical device, which forms an organ-like environment promoting long-term function and survival of the therapeutic cells. Sernova s'engage dans le développement et l'avancement clinique de ses produits contre les maladies métaboliques, hématologiques et autres maladies chroniques utilisant des cellules thérapeutiques transplantées dans un dispositif médical implanté breveté, qui forme un environnement semblable à un organe favorisant la fonction et la survie à long terme des cellules thérapeutiques.

The company’s management believes in building strong and long-lasting collaborations and partnerships that would lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society, in concert with our clinical development programs. La direction de la société croit à la mise en place de collaborations et de partenariats solides et durables qui permettraient au portefeuille de produits de Sernova de progresser rapidement sur le marché, d’améliorer la santé mondiale et d’apporter une valeur ajoutée aux patients et à la société, de concert avec nos programmes de développement clinique.

Indications: Les indications:


Diabetes Diabète

Haemophilia A Hémophilie A

Thyroid disease Maladie thyroïdienne

Clinical studies: Etudes cliniques:


Diabetes US phase I/II clinical study cleared by the FDA Etude clinique de phase I / II sur le diabète, approuvée par la FDA

First-in-human study in Diabetic subjects with hypoglycemia unawareness Première étude chez l'homme chez des sujets diabétiques peu conscients de l'hypoglycémie

Cell Pouch System™


Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device which forms a highly vascularized organ-like environment in the body for the housing, function and long-term survival of therapeutic cells. These therapeutic cells release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Le Cell Pouch System™ est un nouveau dispositif médical préalablement implanté et formant un environnement naturel hautement vascularisé afin d’y loger des cellules thérapeutiques, favorisant leur bon fonctionnement et leur survie dans le corps. Ces cellules thérapeutiques libèrent les protéines ou les hormones nécessaires pour traiter les maladies chroniques comme alternative a l’administration quotidienne de médicaments.


Immune Protection Protection immunitaire


We have shown that cells can be protected using medications that prevent immune system attack within the Cell Pouch™. Nous avons montré que les cellules peuvent être protégées en utilisant des médicaments qui empêchent les attaques du système immunitaire dans la Cell Pouch™.

Microencapsulation technologies house cells within the Cell Pouch chambers and protect the cells from immune system attack. Les technologies de microencapsulation hébergent les cellules dans les chambres à cellules et les protègent des attaques du système immunitaire.

Technologies are in development to make transplanted cells unrecognizable to the immune system. Des technologies sont en cours de développement pour rendre les cellules greffées méconnaissables du système immunitaire.

Sernova’s Cell Pouch™, combined with immune protected therapeutic cells, offers protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic diseases who seek to improve their quality of life. Le Cell Pouch™ de Sernova, associé à des cellules immunitaires protégées, offre une protection contre le système immunitaire avec une option thérapeutique efficace, sûre, à long terme et pratique pour les patients atteints de maladies chroniques qui cherchent à améliorer leur qualité de vie.


Featured News Nouvelles en vedette

July 6, 2021 6 July, 2021

Sernova 2021 AGM Recording

May 25, 2021 25 May, 2021

Loading... Chargement...

Sernova Global Partnership Family Office Presentation

April 28, 2021 28 April, 2021

Loading... Chargement...

Sernova KOL Event on Thyroid Disease with Dr. Sam Wiseman

March 19, 2021 19 March, 2021

Sernova CEO Investor Conference March 2021

December 22, 2020 22 December, 2020

Global News Radio - London, Ont. company makes big leap forward in the fight to cure Type 1 diabetes

October 29, 2020 29 October, 2020

Loading... Chargement...

Sernova - TSX Life Sciences Day


News Releases Communiqués de presse

July 5, 2021 5 July, 2021

Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority

June 30, 2021 30 June, 2021

Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs

June 27, 2021 27 June, 2021

Sernova’s Principal Investigator Presents Interim Data and Positive Patient Outcomes of Phase I/II T1D Study at the American Diabetes Association 8

June 7, 2021 7 June, 2021

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Invest with Sernova Investir dans Sernova

If you are a shareholder, investor, broker, analyst, journalist, investment advisor, or looking to develop business opportunities, please feel free to contact us by email or telephone. Si vous êtes actionnaire, investisseur, courtier, analyste, journaliste, conseiller en placement ou souhaitez développer des opportunités d’affaires, n'hésitez pas à nous contacter par email ou par téléphone.

Sernova is a regenerative medicine company developing therapeutic technologies with multibillion-dollar market potential for each of its clinical indications. Sernova est une société de médecine régénérative développant des technologies thérapeutiques offrant un potentiel de marché de plusieurs milliards de dollars pour chacune de ses indications cliniques.

 

Diabetes patients Patients diabétiques

 

Hemophilia Orphan Indication Indication orpheline de l'hémophilie

 

Sernova is traded on: Sernova est échangé sur:

Subscribe to our Newsletter Abonnez-vous à notre newsletter

*indicates required* requis

By subscribing to our Newsletter you will receive Sernova’s press releases and news as they develop by email. We do not send direct mail, customized online advertising, and we do not share your personal information. We respect your privacy. En vous abonnant à notre newsletter, vous recevrez par e-mail les communiqués de presse et les actualités de Sernova au fur et à mesure de leur développement. Nous n'envoyons pas de publipostage, de publicité en ligne personnalisée et nous ne partageons pas vos informations personnelles. Nous respectons votre vie privée.

Please read our Pour plus d’informations, veuillez lire notre Privacy policypolitique de confidentialité.

Sernova is a Collaborative Team Sernova, c’est aussi les collaborations

We believe in advancing our clinical programs and building strong and long-lasting collaborations and partnerships that will lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society. Nous croyons en la promotion de nos programmes cliniques et en la mise en place de collaborations et de partenariats solides et durables qui permettront au portefeuille de produits de Sernova de progresser rapidement sur le marché, d'améliorer la santé mondiale et d'apporter de la valeur aux patients et à la société.

 

Privacy PolicyPolitique de confidentialité

Updated July 6, 2018

Please read this Policy carefully along with our Legal Notice that describes our Terms of Use for the Website.

By accessing www.sernova.com (the “Website”) you hereby agree with the practices described in this Privacy Policy (the “Policy”)

This Policy applies to all information gathered through the Website and/or any related marketing technique or events.



Information Collection

The information collected is limited to the information that you decide to share with us through the News Dispatch Service, when participating at event or activities or in the general course of business by expressing an interest in obtaining information about Sernova Corp. and our products, such as name, email, phone number, and similar contact information. This information is stored through MailChimp (please refer to MailChimp Privacy Policy at https://mailchimp.com/legal/privacy/).



Information Sharing

Sernova Corp. is the sole owner of any information collected on the Website. We do not sell, share or rent this information to others.



Traffic and Automatic Information Collection

Sernova Corp. maintains log files of the traffic on www.sernova.com. This information is not linked to any personal information that you have provided us. Logs are used to manage traffic, identify content accessed, and IT requirements. Information logged and automatically collected includes without being limited to IP addresses and browser types. This information does not reveal your specific identity.



Cookies

Cookies can be used to provide you with a more personalized experience. The Website may use cookies to make that experience more companionable when you return to the Website. You have the option at all time to decline the use of cookies. If you choose to do so, you may not be able to fully use all features of the Website. You can also delete cookie files at all time from your computer. Those cookies may include first-party cookies (such as the Google Analytics cookies).



Updates

This Policy is a living document and may be amended or updated from time to time without further notice. We encourage you to review the Policy periodically.



Contact

If you have any questions or comments about our policy, you can email us at info@sernova.com or by phone at 1(877) 299-4603 or by mail at

Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8

Mis à jour le 6 juillet 2018

Veuillez lire attentivement cette politique ainsi que notre avis juridique qui décrit nos conditions d'utilisation du site Web.

En accédant à www.sernova.com (le «site Web»), vous acceptez les pratiques décrites dans la présente politique de confidentialité (la «politique»).

Cette politique s'applique à toutes les informations collectées via le site Web et / ou toute technique ou événement marketing associé.



Collecte d'informations

Les informations collectées se limitent aux informations que vous décidez de partager avec nous par le biais du service d’expédition de nouvelles, lorsque vous participez à un événement ou à des activités ou que vous vous intéressez à obtenir des informations sur Sernova Corp. comme nom, email, numéro de téléphone et informations de contact similaires. Ces informations sont stockées via MailChimp (veuillez vous reporter aux règles de confidentialité de MailChimp sur https://mailchimp.com/legal/privacy/).



Partage d'information

Sernova Corp. est l'unique propriétaire de toute information collectée sur le site Web. Nous ne vendons pas, ne partageons pas ou ne louons pas ces informations à des tiers.



Collecte d'informations routières et automatiques

Sernova Corp. gère les fichiers journaux du trafic sur www.sernova.com. Ces informations ne sont liées à aucune information personnelle que vous nous avez fournie. Les journaux sont utilisés pour gérer le trafic, identifier le contenu accédé et les besoins informatiques. Les informations consignées et collectées automatiquement ne sont pas limitées aux adresses IP et aux types de navigateur. Cette information ne révèle pas votre identité spécifique.



Cookies

Les cookies peuvent être utilisés pour vous offrir une expérience plus personnalisée. Le site Web peut utiliser des cookies pour rendre cette expérience plus conviviale lorsque vous revenez sur le site Web. Vous avez la possibilité à tout moment de refuser l'utilisation de cookies. Si vous choisissez de le faire, vous ne pourrez peut-être pas utiliser toutes les fonctionnalités du site Web. Vous pouvez également supprimer des fichiers de cookies à tout moment depuis votre ordinateur. Ces cookies peuvent inclure des cookies de première partie (tels que les cookies de Google Analytics).



Mises à jour

Cette politique est un document évolutif et peut être modifié ou mis à jour de temps à autre sans préavis. Nous vous encourageons à consulter la politique périodiquement.



Contact

Si vous avez des questions ou des commentaires sur notre politique, vous pouvez nous envoyer un courriel à info@sernova.com ou par téléphone au 1 (877) 299-4603 ou par courrier à

Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 05, 2021 5 July, 2021

Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority


LONDON, ONTARIO – July 5, 2021 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, held its annual shareholder meeting (the “Meeting”) via the virtual meeting platform of TSX Trust Company for the following purposes:

1. to elect the Corporation’s board of directors (the “Board”); 2. to appoint the Corporation’s auditor; and 3. to pass ordinary resolutions to amend and restate the Corporation’s Option Plan & Deferred Share Unit Plan (the “Incentive Plan”) for the following purposes: (a) to increase the fixed number maximum of shares reserved for grant of options and (b) to increase the fixed number maximum of Deferred Share Units available for award pursuant to the Deferred Share Unit Plan component of the Incentive Plan.

Results of the Meeting:

• Frank A. Holler, Dr. Mohammad Azab, Jeffrey A. Bacha, Deborah M. Brown, James T. Parsons and Dr. Philip M. Toleikis were elected as members of the Board for the following year; • Davidson & Company, Chartered Professional Accountants, was appointed auditor of the Corporation for another year; and • disinterested shareholders approved the increase in the fixed number maximum of common shares reserved for the grant of options and the increase of the fixed number maximum of deferred share units available for award pursuant to the Incentive Plan.

“I would like to thank our shareholders for their Meeting participation and continuing support. From a financial point of view combined with our latest encouraging interim diabetes clinical results (having established insulin independence in our most advanced study patient for over 14 months) and the stage of our advancing pharmaceutical collaborations, Sernova is in the strongest position in its history,” said Dr. Philip Toleikis, President & CEO of Sernova Corp.

Toleikis continued, “Improving the quality of life for our patients through expansion of our clinical programs and further increasing shareholder value are top priorities as we work to achieve important milestones over the next 6-12 months.”

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Sernova Corp. Tel: (519) 858-5126 investorrelations@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 30, 2021 30 June, 2021

Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs


25-Year Industry Veteran in Clinical/Regulatory Therapeutics Development Joins Sernova’s Executive Team

June 30, 2021 6:00 AM EDT

LONDON, ONTARIO – June 30, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that pharmaceutical industry executive, Frank Shannon has joined Sernova as Vice President, Clinical Development and Regulatory Affairs.

"In his distinguished career focused on North American and International clinical development and regulatory affairs of therapeutic products, Mr. Shannon has developed extensive knowledge and experience in a number of therapeutic areas,” said Dr. Philip Toleikis, President & CEO Sernova Corp. “Importantly, he has worked in both smaller emerging biopharma companies as well as with international pharmaceutical conglomerates and his experience in the execution of combination product clinical development will be invaluable for Sernova’s novel cell therapy development programs."

Dr. Toleikis continued, "With Sernova’s clinical success to date in type 1 diabetes (T1D), we look forward to leveraging Mr. Shannon’s strategic expertise to further progress our ongoing T1D program, including our current US Phase I/II Cell Pouch™ clinical trial, and our local immune protection and stem cell technology initiatives as well as driving clinical development of our other therapeutic programs in thyroid disease and hemophilia A.”

Mr. Shannon has a track record of more than 25 years of proven experience in clinical development and regulatory affairs. He has served in senior level positions within the international medical device, pharmaceutical, and biologic industries where he achieved commercial goals through innovative risk management and execution strategies, to obtain marketing approval of products.

Mr. Shannon most recently served as VP Clinical Development, Regulatory Affairs and Quality at Ripple Therapeutics, a spin-out of Interface Biologics where he served in the same capacity since 2006. Prior to these appointments, he held various senior clinical/regulatory positions at Baxter International, St. Jude Medical, Boehringer-Ingelheim, Hoffmann-La Roche/Roche Laboratories, Inc., Genentech Canada, Inc., and Ciba-Geigy Canada, Ltd.

"I am thrilled to be joining Sernova at such an exciting time in its development,” said Frank Shannon. “I look forward to bringing the learnings from all of my experiences to positively impact Sernova’s expanding clinical programs as the company advances its novel leading regenerative medicine therapeutic programs."

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Sernova Corp. Tel: (519) 858-5126 investorrelations@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 27, 2021 27 June, 2021

Sernova’s Principal Investigator Presents Interim Data and Positive Patient Outcomes of Phase I/II T1D Study at the American Diabetes Association 81st Scientific Sessions


First Patient Successfully Completes Clinical Trial and Shares Study Experiences and Impact

June 28, 2021 6:00 a.m. EDT

LONDON, ONTARIO – June 28, 2021 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that its principal investigator, Dr. Piotr Witkowski, and the clinical trial team for Sernova’s US Phase I/II Type I Diabetes (T1D) clinical trial presented interim data and patient observations from the ongoing study at the American Diabetes Association’s (ADA) 81st Scientific Sessions being held June 25-29th, 2021. Sernova’s data were delivered in a poster presentation entitled “Persistent graft function after allotransplantation into pre-vascularized Sernova Cell Pouch™ device: Preliminary results from the University of Chicago.”

The overall objective of Sernova’s Phase I/II clinical trial is to assess the safety, tolerability and efficacy of its proprietary Cell Pouch transplanted with insulin-producing islets. Study patients eligible to participate in the clinical trial must meet stringent eligibility criteria including, but not limited to, long-standing T1D, severe hypoglycemic unawareness episodes and no glucose-stimulated C-peptide circulating in their bloodstream.

In his poster presentation, Dr. Witkowski confirmed continued safety and tolerability in all six enrolled study patients. In addition, the two longest-treated patients continue to demonstrate defined and meaningful clinical benefit in line with previously established key T1D efficacy indicators including reduction in HbA1c, reduction or elimination of severe hypoglycemic events (SHE), reduction or elimination of daily injectable insulin, detection of C-peptide in the patients’ bloodstream, and improvement in glucose control as measured by continuous glucose monitoring (CGM). The remaining patients are advancing through the study at different stages and their progress continues to be evaluated. The study plans to enroll a total of seven patients and is actively screening for the recruitment of the final patient.

Importantly, the most advanced patient showing positive clinical benefit achieved with Cell Pouch and transplanted islets, and then receiving a top up single infusion of islets (via portal vein), has successfully completed the study protocol. Data from this patient support the long-term safety of Sernova’s Cell Pouch and, importantly, the patient has now remained insulin independent (no requirement for injectable insulin) for 14 months with optimal glucose control. The patient recently gave Sernova permission to share the impact and their personal experience of being the first recipient of the Cell Pouch in Sernova’s T1D Phase I/II clinical trial:

“After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is to be free of always thinking of how to manage my diabetes. After having T1D for 47 years with approximately 21,535 injections of various cow/pig, synthetic insulins, 34,310 finger sticks, 1,460 urine tests, 15 years on the pump, carbohydrate counting, blood tests, low blood sugar reactions, and doctors…doctors and more doctors’ visits, I have now been free of the need for injectable insulin for 14 months. My Sernova team of invaluable scientists, doctors, engineers, and Dr. Witkowski, and the University of Chicago's support staff have done this truly amazing feat right in the middle of a worldwide pandemic! My only wish is that it could have been done sooner.”

Said principal investigator Dr. Witkowski, “As a clinician-scientist and surgeon, success is typically based on objective outcome measures. Although crucial, often what is missing is the perspective of the patients and the impact on their lives, in their own words. I am thrilled with the transformative and meaningful impact that our clinical trial has had and continues to have on the life of our first patient and I would like to extend my congratulations to this individual who successfully completed the Sernova study with the positive outcome of insulin independence. As we continue to optimize conditions within the designed clinical protocol, I am excited and proud to be a part of the evolution of Sernova’s novel cell therapy approach for the treatment of T1D.”

“Sernova’s ultimate goal is to establish a ‘functional cure’ based on our Cell Pouch technologies for all people with T1D”, said Dr. Philip Toleikis, President & CEO of Sernova Corp. “As we advance our clinical program we thank our patients and physicians as well as our participating pharmaceutical and medtech collaborators who have assisted us to advance beyond established, but insufficient, therapies. Good science is a step-by-step process, and each advancement brings us closer to our goal. It is very timely that we celebrate our first trial patient’s success as the world marks the 100th anniversary of the discovery of insulin.”

ABOUT SERNOVA'S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The primary objective of the study is to assess the safety of the Cell Pouch following implantation and islet transplantation. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova's clinical trial prior to receiving the Cell Pouch and islets are incapable of producing C-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow-up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on the clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investor Relations

Sernova Corp.

Tel: (519) 858-5126

investorrelations@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. It should also be noted that patient views and outcomes within the clinical trial may differ with each patient dependent on multiple factors. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 07, 2021 7 June, 2021

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference


Multiple patients with sustained clinical benefit, including positive fasting serum C-peptide (a biomarker of insulin produced by Sernova’s Cell Pouch islets) detected in their bloodstream

June 7, 2021 6:00 a.m. EDT

LONDON, ONTARIO – June 7, 2021 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company today announced that its principal investigator, Dr. Piotr Witkowski, presented new preliminary data from Sernova’s ongoing U.S. Phase I/II T1D clinical trial at the University of Chicago. Dr. Witkowski’s presented the data at the American Transplant Congress (ATC) 2021 Virtual Connect conference on Saturday June 5, 2021.

The overall objective of the clinical trial is to assess the safety, tolerability, and efficacy of the Cell Pouch with insulin-producing islets. In addition to other criteria, prior to entry into the study, the patients must demonstrate long-standing T1D with severe hypoglycemic unawareness episodes and no glucose-stimulated C- peptide circulating in their bloodstream.

Dr. Witkowski’s presentation entitled “Islet Allotransplantation Into The Pre-Vascularized Sernova Cell PouchTM Device - Preliminary Results Of The Phase I/II Prospective, Open-Label, Single-Arm Study At University of Chicago” highlighted the following key points:

• 6 patients are implanted with Cell Pouches and continue to meet the study’s primary safety endpoint;

• 5 patients have now been transplanted with at least one dose of therapeutic cells (insulin producing islets) and are in different stages of the clinical trial; and

• most significantly, positive fasting serum C-peptide has been detected in the bloodstream of 4 patients so far. C-peptide is a biomarker for insulin produced by the islets in the Cell Pouch.

In addition to the continued confirmation of ongoing safety and tolerability in all currently enrolled patients, Dr. Witkowski provided further updates on the longest treated study patients. These patients continue to show defined clinical benefit associated with ongoing efficacy indicators including:

• reduction/elimination in the need for daily injectable insulin

• continued improvement, i.e. reduction/elimination, in Severe Hypoglycemic Events (SHE);

• persistent detection of fasting and stimulated C-peptide in patients’ bloodstream;

• reduction in HbA1c; and

• continued improvement of glucose control determined through patient blinded Continuous Glucose Monitoring (CGM) and measured by reduction of Time Above Range (TAR) and increase of Time in Range (TIR).

As previously reported, the most advanced patient in the study, who had achieved a ‘functional cure’ (requiring no injectable insulin) and had been insulin independent for 9 months, has now been insulin independent for 14 months with optimal glucose control.

“I believe Sernova is the first company in the world to demonstrate a subcutaneous vascularized device with therapeutic cells able to produce insulin in the bloodstream across multiple patients with the most severe diabetes. This is a remarkable feat. As the study progresses and our patient dataset continues to build, I am more confident than ever of the potential of Sernova’s regenerative medicine therapeutic platform,” said Dr. Philip Toleikis, President and CEO of Sernova. “Our vision of improving the lives of people suffering from diabetes with a ‘functional cure’ is another step closer to becoming a reality.”

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investor Relations

Sernova Corp.

Tel: (519) 858-5126

investorrelations@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 01, 2021 1 June, 2021

Sernova Announces American Transplant Congress 2021Virtual Connect Abstract Presentation


June 1, 2021 7:00 am ET LONDON, ONTARIO – June 1, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a presentation at the upcoming American Transplant Congress (ATC) Virtual Connect to be held June 4 - 9, 2021.

The live presentation entitled “Islet Allotransplantation Into the Pre-Vascularized Sernova Cell PouchTM Device - Preliminary Results from University of Chicago” will be available to conference attendees on Saturday, June 5, 2021 at 6:30pm ET.

ABOUT SERNOVA’S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT THE AMERICAN TRANSPLANT CONGRESS The American Transplant Congress (ATC) is the joint annual Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST). ATC provides a forum for exchange of new scientific and clinical information relevant to solid organ and tissue transplantation and brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals, and other transplant professionals. The educational offerings provide attendees the opportunity to learn cutting-edge advances in research and promotes the exchange of ideas and practice in the field of solid organ and tissue transplantation. ATC is an annual Congress that welcomes over 5,000 transplant professionals to present cutting-edge science that covers all organ types and offers insight into the future of the field and patient care.

ABOUT ATC 2021 VIRTUAL CONNECT ATC 2021 Virtual Connect, is the ATC’s new, enhanced virtual meeting experience for transplantation professionals taking place June 4-9, 2021. This year’s all-virtual format will feature a robust program of new scientific and clinical information, discussions around care and management, and socioeconomic, ethical, and regulatory issues relevant to organ and tissue transplantation. This year’s program will also feature new COVID-19 content pertinent to the field of transplantation.

FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Sernova Corp. Tel: (519) 858-5126 Investorrelations@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 17, 2021 17 May, 2021

Sernova to Present at Global Partnership Family Office – HealthCare & Biotechnology TSX Showcase


May 17, 2021 9:00 AM ET

LONDON, ON – May 17, 2021 -- Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the virtual Global Partnership Family Office – Healthcare & Biotechnology TSX Showcase on May 19th, 2021. The Showcase is hosted by London, UK based International Deal Gateway (IDG).

The event is by invitation only and includes a selected group of inspiring leaders from innovative public companies in the healthcare, biotechnology and life sciences sector. Five leading companies listed on the TSX or TSX Venture have been selected to present live, via video, to GPFO investors.

“Deal Gateway’s exclusive virtual events give innovative leaders the opportunity to introduce their companies to a very hard to reach audience of family offices and access new pools of capital in London, Geneva, Zurich and other key markets,” said Elizabeth Priestman, CEO of IDG.

“Sernova is delighted to have been selected by the TSX to present to this exclusive group of sophisticated investors,” said Dr. Philip Toleikis, President and CEO of Sernova. “This presentation aligns with our goal to increase the percentage of longer-term oriented institutional investors amongst our shareholder base who understand the value of innovative technologies. We look forward to presenting to them and outlining the potential of Sernova’s innovative regenerative medicine platform, including potentially providing a ‘functional cure” for diabetes and other chronic diseases.”

Following the event, a recording will be available at www.sernova.com.

Selected Company Achievements

● Integrated regenerative medicine therapeutic platform solution including an implantable device with local immune protection (Conformal Coating Technology) that could eliminate the need for immunosuppressive medications to protect cells from immune system attack.

● First and only regenerative medicine therapeutics platform company to demonstrate an implantable well- vascularized subcutaneous cell transplant device technology achieving persistent islet graft function and clinical benefit as presented in the most advanced study patients in its ongoing US Phase I/II diabetes clinical trial.

● Demonstrated preclinical proof-of-concept showing improvement in blood clotting with human cells using an ex vivo gene therapy approach for hemophilia A

● Demonstrated preclinical proof-of-concept with transplanted human thyroid tissue for management of hypothyroid disease.

● Multiple research collaborations in place with pharmaceutical industry leaders.

About Global Partnership Family Office (GPFO) and International Deal Gateway (IDG)

International Deal Gateway's Family Office Events provide a unique opportunity for public and private companies to gain access to an exclusive group of 2,400 ultra-high net worth investors and family offices throughout Europe through their long-standing relationship with GPFO. Together, IDG and GPFO look forward to hosting the TSX sponsored Healthcare & Biotechnology Showcase, a collection of extraordinary select companies working to improve health outcomes with a focus on longevity, healthcare, biotechnology and data.

GPFO has been the 'eyes and ears' of the global family office community for over a decade. Providing salient, timely and impartial briefings, insights and opportunities to its membership.

Dr. Michael J. Oliver, GPFO founder, "We have been delighted to grow our partnership with IDG over the years, providing our community with insights from the brightest minds and leaders from across the Atlantic, offering a bridge for many of our network who have deep familial and business ties to Canada and the US."

About Sernova

Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

CONTACTS:

Sernova Corp

Dominic Gray

Head of Communications

(519) 858-5126

dominic.gray@sernova.com

www.sernova.com

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials and the potential of local immune protection technologies. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 04, 2021 4 May, 2021

Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors


May 4, 2021 9:00 AM ET

LONDON, ONTARIO – May 4, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that seasoned pharmaceutical industry executive, Dr. Mohammad Azab, MB ChB, MSc, MBA, has been nominated by the Company to its Board of Directors.

“Dr. Azab’s extensive knowledge and experience in the pharmaceutical industry, as well as his many industry connections, make him an excellent fit for the Board of Sernova, particularly as the Company expands its clinical development programs for the treatment of chronic diseases such as diabetes, thyroid and rare diseases,” said Frank Holler, Chairman of the Board of Sernova. “Dr. Azab’s appointment further supports the Company’s near-term goal to bolster its Board of Directors, as well as Scientific Advisory and Global Advisory Boards, in line with our expanding research, development and business activities.”

Dr. Azab served as President and Chief Medical Officer of Astex Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and development of drugs in oncology and other disease indications. As of November 2020, upon retirement from his management role, Dr. Azab has served as the Chair of the Board of Directors for Astex Pharmaceuticals, Inc, which is now a wholly-owned subsidiary of Otsuka Pharmaceuticals. Previously, Dr. Azab served as President and CEO of Intradigm Corporation, a developer of siRNA cancer therapeutics. Prior to this, Dr. Azab served as Executive Vice President of Research and Development and Chief Medical Officer of QLT Inc., and in several leadership positions at AstraZeneca in the United Kingdom and Sanofi Pharmaceuticals in France. Dr. Azab holds his medical degree (MB ChB) from Cairo University and an MBA from the Richard Ivey School of Business, Western University, Ontario. He received post-graduate training and degrees in oncology research from the University of Paris-Sud and biostatistics from the University of Pierre et Marie Curie in Paris, France.

“I am excited to be nominated to join Sernova’s Board of Directors,” said Dr. Mohammad Azab. “I intend to bring my experience and additional perspectives to support Sernova and its management team as the company progresses it novel regenerative medicine therapeutic programs with the aim to provide a ‘functional cure’ for patients suffering from chronic diseases.”

Dr. Azab has more than 30 years of experience in clinical research, business management and led the global development of several drugs currently approved in oncology and other therapeutic areas. Currently, he also serves on the board of directors of NASDAQ listed companies, Xenon Pharmaceuticals Inc. (XENE), and Durect Corporation (DRRX).

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp.

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 28, 2021 28 April, 2021

Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease


April 28, 2021 9:00 AM ET

LONDON, ONTARIO – April 28, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, announced today the highlights of its first virtual Key Opinion Leader (KOL) event on thyroid disease.

The KOL event featured a presentation by Dr. Sam Wiseman, a leading surgeon and internationally recognized expert in the management of thyroid and parathyroid disease. In his presentation, Dr. Wiseman discussed current treatment options and the potential for a novel cell therapy approach for the treatment of postoperative hypothyroidism using Sernova’s Cell Pouch™. The presentation was followed by a Q&A session with attendees.

“I’m very excited about this program because as surgeons, we will be able to offer our patients a treatment option that could allow for avoidance of postoperative hypothyroidism requiring life-long dependence on thyroid medication,” said Dr. Sam Wiseman. “Our preclinical study evaluating transplantation of human thyroid tissue into Sernova’s Cell Pouch has shown promising results. I believe this very exciting new approach represents a critical step towards an entirely new treatment option for post-thyroidectomy hypothyroidism."

Dr. Wiseman's presentation and the subsequent Q&A session are now available on Sernova's website at www.sernova.com and on Sernova’s social media channels.

ABOUT SERNOVA'S THYROID PROGRAM

Sernova's approach for treating postoperative hypothyroidism is to transplant a portion of the thyroid gland being removed into a pre-implanted vascularized Cell Pouch™ to recover thyroid function. In collaboration with Dr. Wiseman, preclinical proof of concept study conducted under a grant from the British Columbia Transplant Foundation is contributing to advancing Sernova's plans to conduct clinical assessment of this novel approach. Sernova's overall treatment goal is to preserve thyroid function, and improve patient quality of life, relative to current treatments.

Thyroidectomy is commonly performed for management of cancer, and for treatment of benign (non- cancerous) disease that includes nodules, goitre and hyperthyroidism. It is estimated that about 150,000 thyroidectomies are performed in the US annually, with most individuals undergoing thyroid surgery eventually being diagnosed with benign conditions. Patients undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy, require life-long oral postoperative thyroid hormone replacement.

Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, some patients may suffer from deleterious side-effects including body weight gain, fatigue, and depression, with a resultant negative impact on quality of life, and significant costs to the healthcare system. We believe Sernova's development of new therapeutic strategies to treat post-surgical hypothyroidism has the potential of addressing an important unmet medical need.

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, stem cell-derived cells and tissues) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp.

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 21, 2021 21 April, 2021

Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach


April 21, 2021 9:00 AM ET

LONDON, ONTARIO – April 21, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that it will host a virtual Key Opinion Leader (KOL) event on thyroid disease, current treatment options and the potential of a novel cell therapy treatment approach for postoperative hypothyroidism. The event will take place on Tuesday April 27th, 2021, at 1:00 PM ET.

The event will feature a presentation from Dr. Sam Wiseman, a leading academic thyroid/parathyroid surgeon and internationally recognized expert in the management of thyroid and parathyroid disease.

"This KOL event will provide the unique opportunity for our investors to learn about thyroid disease, current treatments, and exciting advancements towards a novel cell therapy treatment approach aimed to provide a functional cure for patients suffering from postoperative hypothyroidism," said Dr. Philip Toleikis, President and CEO of Sernova. "Participants will also be able to enter into a conversation through a Q&A period with Dr. Wiseman, a prominent physician in the management of thyroid disease."

Dr. Wiseman's presentation will be made available on Sernova's website before the call. All questions to Dr. Wiseman, can be submitted to info@sernova.com prior to the call.

To register and access the Zoom link for this event, please click:

https://zoom.us/webinar/register/2016189463384/WN_LF8impNgRzqpbSMeLdeMww

Following the event, a recording will be available at www.sernova.com.

ABOUT SERNOVA'S HYPOTHYROID PROGRAM

Sernova's immediate approach in treating hypothyroid disease is to transplant healthy thyroid tissue following thyroidectomy (removal of the thyroid gland) into the pre-implanted vascularized Cell Pouch to recover the normal function of the thyroid gland. In collaboration with Dr. Wiseman, preclinical proof of concept work conducted under a grant from the British Columbia Transplant Foundation is contributing to advancing Sernova's plans to conduct clinical assessment of the Cell Pouch with transplanted thyroid tissue in patients suffering from hypothyroid disease. Sernova's treatment goal is to preserve thyroid function and improve patient quality of life relative to current treatments.

Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non- cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000 thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation are diagnosed with benign diseases after their procedure. Patients with Grave's disease and thyroid nodules undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid hormone replacement.

Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, patients often suffer from deleterious side-effects including weight gain, depression, headaches, and cardiovascular disease, with resultant negative impact on quality of life, and significant costs to the healthcare system. We believe Sernova's development of new therapeutic strategies to overcome hypothyroidism has the potential to meet an important unmet medical need.

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp.

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 14, 2021 14 April, 2021

Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board


Sernova Expands Scientific Advisory Board Expertise for its Innovative Cell Therapy Therapeutic Applications in Endocrine Disorders Including Thyroid Disease

April 14, 2021 9:00 a.m. EST

LONDON, ONTARIO – April 14, 2021 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading clinical-stage company developing regenerative medicine therapeutic technologies for the long-term treatment of chronic diseases, today announced the appointment of Dr. Sam Wiseman to its Scientific Advisory Board (SAB).

“We are pleased to welcome Dr. Wiseman to Sernova’s Scientific Advisory Board,” said Dr. Philip Toleikis, President & CEO Sernova Corp. “Dr. Wiseman’s internationally recognized leadership in surgical treatment of thyroid and parathyroid disease and his forward-thinking interest in Sernova’s development of novel cell therapy-based applications will be a great asset as we seek to expand the clinical applications of our cell pouch platform.”

“The importance of the thyroid gland in controlling everyday bodily functions is often underappreciated. For people who have their thyroid gland removed, the solution relies on lifelong dependence on medication,” said Dr. Sam Wiseman. “Sernova’s cell therapy approach aims at providing a functional cure and improving the quality of life for these patients by allowing them to reduce or potentially eliminate daily thyroid hormone treatments. I am excited to join Sernova’s Scientific Advisory Board and bring my expertise to support them in the development of novel cell-based approaches for treatment of thyroid disease and potentially other endocrine diseases.”

Dr. Sam Wiseman is an academic thyroid/parathyroid surgeon and internationally recognized expert in the management of thyroid and parathyroid disease. He is Professor of Surgery in the Faculty of Medicine at the University of British Columbia (UBC) and is an attending surgeon at St. Paul’s Hospital in Vancouver. Dr. Wiseman attended medical school and completed residency training in General Surgery, at the University of Manitoba, obtaining a Fellowship in Surgery from the Royal College of Physicians and Surgeons of Canada in 2000. At Roswell Park Cancer Institute, he completed fellowships in Head & Neck Surgery, Surgical Oncology, and Oncology Research. Dr. Wiseman joined the staff at St. Paul's Hospital, and the University of British Columbia in 2003. He is also a Fellow of the American College of Surgeons, and a Consultant Surgical Oncologist at the British Columbia Cancer Agency (BCCA). He currently serves as the Research Head for the Department of Surgery at Providence Health Care and is the Chair of the Endocrine Tumour Group of the BCCA. He has authored more than 150 peer-reviewed scientific publications, numerous book chapters, and served as a senior editor of the medical textbook, Gray’s Surgical Anatomy. Dr. Wiseman’s research has been presented globally and he has received numerous awards and honours throughout his career that include a Michael Smith Foundation for Health Research Scholar Award and Canada’s Top 40 Under 40 Award. He is passionate about education and mentors and supervises many trainees, both clinically and in research. He is committed to providing new therapeutic options and treatment approaches for patients suffering from thyroid/parathyroid diseases with the ultimate goal of improving quality of life for these people.

ABOUT SERNOVA’S THYROID DISEASE PROGRAM

Sernova is utilizing its Cell Pouch Platform as a potential treatment for hypothyroid disease. Our approach is to transplant a patient’s own healthy thyroid tissue following thyroidectomy into the pre-implanted vascularized Cell Pouch to preserve the normal thyroid function and reduce or eliminate the need for lifelong daily thyroid replacement therapy. Sernova plans to conduct clinical assessments of the Cell Pouch with transplanted thyroid tissue in patients suffering from post-surgical hypothyroidism with the aim of preserving thyroid function and improving patient quality of life.

Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non- cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000 thyroidectomies are performed in the US yearly. Patients with Grave’s disease and thyroid nodules undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid hormone medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, patients often suffer from deleterious side-effects including weight gain, depression, headaches, and cardiovascular disease, with resultant negative impact on quality of life, and significant costs to the healthcare system. The development of new therapeutic strategies to overcome hypothyroidism remains an important unmet medical need.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, hypothyroidism, hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.